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Tight junctions are the apical cell-cell adhesion that regulate paracellular permeability and are critical for epithelial cell polarity.
Moleculararchitectureoftightjunctionhasbeenstudiedextensively,whichhasconﬁrmedthatclaudinfamilyofproteinsisintegral
component of tight junction. Loss of cell-cell adhesion is central to the cellular transformation and acquisition of metastatic
potential; however, the role of claudin family of proteins play in a series of pathophysiological events, including human carcinoma
development, is only now beginning to be understood. Several claudin mouse knockout models have been generated and the
diversityofphenotypesobservedclearlydemonstratestheirimportantrolesinthemaintenanceoftissueintegrityinvariousorgans
andsuggestthatclaudins alsoparticipateincellular contexts otherthantightjunctions.Themechanisms ofclaudinregulationand
their exact roles in normal physiology and disease are being elucidated, but much work remains to be done. In this review, we have
discussed the conceptual framework concerning claudins and their potential implication in cancer. We predict that next several
years will likely witness a boom in our understanding of the potential role of claudins in the regulation of tumorigenesis, which
may, in turn, provide new approaches for the targeted therapy.
1.Introduction
Genetic alterations in various genes responsible for the
maintenance of the normal epithelial phenotype has come
forward as a major cause for the deregulation of normal
epithelial physiology however, it is well established that
genetic mutations are correlated with various environmental
stimuli. In addition, direct exposure to various environ-
mental carcinogens is considered one of the most plausible
sources of inducing neoplasia. In general, mammalian body
is very selective in its absorptive behavior which is regulated
by size as well as charge of the molecules which body is
being exposed. Tight junctions, the most apical cell-cell
adhesion, owing to their cellular location are responsible for
thisselectionandanyqualitativeorquantitativederegulation
of the TJ characteristics could potentially change the nor-
mal equilibrium maintained, resulting in abnormal cellular
physiology. Also, the normal regulation of growth factor
receptor activation due to diﬀerential distribution of the
receptor and the respective ligands can be compromised due
to irregular tight junctions [1]. Disruption of tight junction
barrier function and changes in permeability properties have
been shown to be associated with a number of pathologic
conditions such as kidney disorders, inﬂammatory bowel
disease, pulmonary edema, diarrhea, and jaundice [2–5].
Proper cell-cell and cell-extracellular matrix interactions
are essential for normal functioning of an epithelial cell
and it is known that various cell adhesion proteins such
as E-cadherin, β-catenin, or β1-inetgrin perform functions
diﬀerent than their normal cell adhesion function upon loss
of normal cell-cell or cell-ECM adhesions [6]. A similar
hypothesis could be postulated for the proteins forming the
tight junctions, which could probably play a central role in
the neoplastic process via coupling of the extracellular milieu
to intracellular signaling pathways and the cytoskeleton. In
this regard, ZO-1, a tight junction protein, binds with the
Y-box transcription factor ZONAB that has been shown to
increase cell proliferation and decrease diﬀerentiation [7].
Recently, Symplekin, yet another transcription factor, was
shown to increase tumorigenicity of the colon cancer cells
through the upregulation of claudin-2 and ZONAB [8].
Importantly, ZO-1 and ZONAB are localized at the tight
junction in diﬀerentiated and polarized epithelial cells while
translocate to the cell cytoplasm/nucleus in proliferative or2 Journal of Oncology
dediﬀerentiated cells [9] .I nt h i sp a p e r ,w ew i l ls u m m a r i z e
the current knowledge regarding the role of tight junction
with speciﬁc emphasis upon the claudin family of proteins in
cancer and potential cause and eﬀect association between the
expression of speciﬁc claudin family members with tumor
growth and progression.
2. Tight Junction and Tumorigenesis
Tight junctions (TJs) are the most apical intercellular
junctions in epithelial and endothelial cells. The two major
functions deﬁned for tight junctions are the regulation of
paracellular permeability through its barrier function and
maintenance of the cell polarity through the fence function
[10, 11]. These considerations of polarity, compartmen-
tation, and barrier function are the underpinnings of a
fascinating development in biomedicine. The fence function
of tight junction helps in maintaining cell polarity, thus
preventing intermixing of molecules in the apical membrane
with those in the lateral membrane. There are certain
times in any area of scientiﬁc research where one can
witness a new concept taking shape and gaining acceptance.
The involvement of epithelial barrier breakdown in the
development of epithelial neoplasia is such a concept at
present that is gaining acceptance and importance, although
it is important to mention that the “roots” of this concept
go back many years. The function of tight junction that is
deeplyinvolvedincancercellbiologyisepithelialparacellular
permeability and the loss of cell polarity [12, 13].
The concept of epithelial barrier breakdown involves
the three mutually interrelated elements that have key
consideration in neoplastic growth and development: (i) as
a result of cell polarity, functional growth factor receptors
are normally situated on the basal-lateral cell surface facing
interstitial ﬂuid and the bloodstream; (ii) growth factor
proteins (the ligands for these receptors) are frequently
compartmentalized at very high concentrations in luminal
ﬂuids within epithelial tissues; and (iii) early in the process
of neoplasia, “distortions” occur in TJs such that relatively
large solutes may pass across epithelial barriers that normally
restrict their movement, a phenomenon one might call
“lesional leak.” For example, in colorectal cancer, expression
of claudin-2 that has been correlated with epithelial perme-
ability increases while expression of claudin-1 or 7 that are
correlated with increased TER is either mislocalized or is
decreased [14, 15]. Thus, the concept has developed that TJ
disruption in premalignant neoplastic tissue can increase the
likelihood that it will develop into a frank carcinoma because
of the continuous stimulation of cell division of initiated
(premalignant) cells that follows breakdown of the natural
barrier between growth factors and their receptors.
Studies have shown that the epithelial tight junctions
are dynamic structures and are subject to modulation
during epithelial tissue remodeling [16], wound repair [17],
inﬂammation [18], and transformation into tumors [19].
The association of abnormal TJ function and epithelial
tumor development has been suggested by earlier studies
showing alterations in the TJ structures of epithelial cancers
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Figure 1: Schematic presentation of tight junction location
between the epithelial cells and paracellular transport. Lower part
represents tight junction strands and interaction of their major
components.
[20]. In vitro studies using epithelial cell lines demonstrated
that monolayers can be transformed into multilayered polyp
like structures by oncogenes, such as K-ras [21], or by
phorbolestertumorpromoters[22].Epithelialmultilayering
was associated with increased TJ permeability [22, 23],
activation of protein kinase C-α [24] and phosphorylation
of TJ proteins [25].
3. Claudins:Tight JunctionIntegralproteins
Tight junctions are complex cellular entities and have always
been understudied especially because of the lack of the
precise knowledge of the proteins constituting them and also
due to the diﬃculties associated with establishing in vivo
or in vitro models to determine the true functional charac-
teristics associated with these proteins. Although multiple
proteins with diverse biological functions including tumor
suppressors such as APC, PTEN, or cell polarity proteins
such as Par-3, aPKCλ are localized at the tight junction
location, it was only in the late 1980s that biochemical and
immunolocalization studies identiﬁed the 225 kDa protein
zonulaoccludens-1(Z0-1)astheﬁrstpolypeptideexclusively
associatedwiththeTJ[26].ZO-2andZO-3,whicharehighly
related to ZO-1, were identiﬁed later [27–29]. However,
genetic manipulation studies suggested that the ZO-family
of proteins, although associated with TJ are not the TJ
integral proteins. Immunolocalization by both light and
electron microscopy further revealed that all three known
ZOs (ZO-1, ZO-2, and ZO-3) are located exclusively at the
cytoplasmic surface of TJs in the immediate vicinity of the
plasma membrane and not in the plasma membrane. Since
then, a number of integral membrane proteins associated
withtheTJhavebeenidentiﬁedduringrecentyearsincluding
occludin[30],junctionaladhesionmolecule(JAM)[31],and
the claudin family of proteins, which consists of at least 24
members [32]( Figure 1). The JAMs are immunoglobulinJournal of Oncology 3
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Figure 2: Schematic representation of structure of claudins. Claudins are transmembrane proteins with domains 1 to 4 (TMD-1, TMD-2,
TMD-3, and TMD-4) and extracellular loops represent promising target for therapy. The –COOH terminal of claudins contains PDZ-
binding domain which undergoes posttranscriptional modiﬁcation that is important for signal transduction.
(Ig)-like single-span transmembrane molecules and mediate
Ca2+-independent adhesion. They are concentrated at TJs as
well as AJs, not only in polarized epithelial and endothelial
cells but also in hematopoietic cells of all lineages [33]. These
proteins can form homodimers or heterodimers to produce
paired strands between adjacent cells, thereby determining
the characteristic permeability properties of diﬀerent epithe-
lialtissues[34].Occludinwithfourtransmembranedomains
was identiﬁed as the ﬁrst TJ-speciﬁc integral membrane
protein. However, occludin-deﬁcient visceral endoderm cells
still bore a well-developed network of TJ strands, pointing
to the existence of as-yet-unidentiﬁed TJ-speciﬁc integral
membrane proteins [35].
Using the same liver fraction employed to identify
occludin, and by means of a sucrose step gradient, a
single 22 kDa band was discovered as a putative novel TJ
integral protein. Peptide sequencing revealed two proteins
in this band that were subsequently named claudin 1 and
2[ 32]. The name claudin derives from the Latin word
“claudere” which means to close. Now, outcome of multiple
studies since the initial discovery of claudin-1 and -2, has
established that the claudin family of proteins are the major
integral membrane proteins forming the backbone of tight
junctions [32, 36, 37]. The claudin family consists of 24
known transmembrane proteins exhibiting distinct tissue-
and development-speciﬁc distribution patterns [37, 38].
They are detected in both epithelial and endothelial cells
and form a complex with occludin and/or JAMs [32, 39].
Claudins encode 20–27 kDa proteins with four transmem-
brane domains, two extracellular loops where the ﬁrst one
is signiﬁcantly longer than the second one, and a short
carboxyl intracellular tail (Figure 2). The last amino acids of
this tail are highly conservedwithin the familyand constitute
PDZ binding motifs: claudins 1–9 and 17 S/TYV, claudins
10 and 15 AYV, claudin 11 AHV, claudin 12 HTT, claudin
13 LDV, claudins 14, 18 and 20 DYV, claudin 16 TRV, and
claudin 19 DRV. Through these motifs, claudins are linked
to the TJ PDZ containing proteins ZO-1, ZO-2, ZO-3 [40],
PATJ [41] and MUPP1 [42] .An u m b e ro fo t h e rc y t o s o l i c
and nuclear proteins which includes regulatory proteins
Rab3b, Rab13, tumor suppressors like PTEN, transcription
factors like ZONAB, and HuASH1 have also been shown to
interact directly or indirectly with tight junction complex
[9, 43–45]. These interactions suggest that tight junctions,
in addition to acting as barriers to paracellular ﬂow of
solutes, may play an important role in regulating other
cell functions, such as proliferation and tumor suppression.
For example, mutation in CLDN14 leads to nonsyndromic
recessive deafness [46] and the mutated CLDN16 gene has
been associated with hereditary hypomagnesemia [47]. Mice
lacking claudin11 (also known as Occludin Sertoli Protein)
have demonstrated the absence of TJ strands in myelin
sheets of oligodendrocytes and Sertoli cells in the testis
[48]. They show male sterility as well as delayed axonal
conduction rates in the central nervous system. However,
emerging details from a boom of studies related with the
claudins in cancer have implicated claudin family members
in a wide range of human cancer and in a tissue speciﬁc
manner.
4.ClaudinsandCancer
Since their discovery, literature regarding the status of clau-
dins in various cancers is constantly expanding, and in4 Journal of Oncology
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lines indicate indirect pathways and solid lines represent direct pathways. Abbreviations: HDAC-Histone deacetylase; MAPKs- mitogen-
activated protein kinases; RUNX3—Runt-related transcription factor 3; FOXO1—Forkhead box O-1; PAR3/PAR6-Partitioning defective;
PI3K- Phosphoinositide 3-kinases; NF-κB - nuclear factor kappa-light-chain-enhancer of activated B cells.
contrast to the general thought that claudins expression
would decrease during tumorigenesis as tight junctions
are lost during cellular transformation, claudins expression
seems to change in a tissue speciﬁc manner. Tan et al. [49]
have shown that the expression and distribution of claudin-
1 is associated with cell dissociation status in pancreatic
cancer cells through mitogen-activated protein kinase 2
activation. By contrast, claudin-7 has been found to be
decreased in invasive ductal carcinomas [50], head and
neck cancer [51] and metastatic breast cancer [52]. On the
other hand, Claudin-3 and -4 are frequently elevated in
variouscancersincludingpancreaticductaladenocarcinoma,
prostate, uterine, ovarian cancer [53] and breast cancer [54]
while hepatocellular and renal carcinomas expressed lower
levels of claudins-4 and -5 [55]. While, lower expression of
claudin-2 was also seen in breast and prostatic carcinomas,
expressions of claudin-1 and claudin-7 that were unde-
tectable in normal cervical squamous epithelium increased
in the cervical neoplasia [55, 56]. Intriguingly, recent studies
have shown that expression of certain claudins especially
claudin-1 and claudin-4 increases during metastasis and
genetic inhibition of their expression has profound eﬀect
on the metastatic abilities of cancer cells though in a tissue
speciﬁc fashion [57–59]. In Table 1,w eh a v es u m m a r i z e d
the status of the expression of claudin family members in
diﬀerent cancer types. Intuitively, the mechanism by which
decreasedclaudinexpressionmightleadtothecompromised
TJ function and, thus, neoplasia is easy to comprehend, but
how increased claudin expression contributes to neoplastic
progression,asdescribedhereandbyothers,islessclear.One
plausible mechanism is that upregulation or aberrant tissue
expression of certain claudins may contribute to neoplasia
by directly altering TJ structure and function. Furthermore,
it is postulated that claudins may also aﬀect cell signaling
pathways. Claudin proteins are likely involved in signaling
pathways via binding domains to ZO-1 at their carboxyl
terminus [40]. Cell-cell adhesion proteins are known to play
important role in cellular transformation when displacedJournal of Oncology 5
from their normal membrane localization and could serve
as oncogenic molecule. The best studied molecules is β-
catenin, which although serve as cell-cell adhesion molecules
when expressed in its normal cellular localization, β-catenin
becomes oncogenic [60]. A similar functional heterogeneity
could be postulated for claudins however further studies are
needed to support such a notion.
In this regard, we have recently demonstrated biological
signiﬁcance of altered claudin-1 expression in colon cancer
cells. An increase in claudin-1 expression was observed in
human primary colon carcinoma and metastasis samples
and in the cell lines derived from primary and metastatic
tumors as compared to their normal counterparts [59]. An
important ﬁnding of our study was the nuclear localization
of claudin-1 in a signiﬁcant subset of colon cancer samples,
particularly among the subset of liver metastatic lesions.
Nuclear localization of several cell junction proteins (β-
catenin, ZO-1, ZO-2) is known to be correlated with
oncogenic transformation and cell proliferation [61, 62].
As mentioned above, β-Catenin plays a well-characterized
dual role in cell adhesion (membrane localized) and in
signal transduction (cytoplasmic and nuclear) leading to the
epithelial cell transformation. Further, mutants of the TJ
protein ZO-1 that no longer localize at the plasma mem-
brane induce a dramatic epithelial-mesenchymal transition
(EMT) of Madin-Darby canine kidney I cells [63]. Similarly,
genetic manipulations of claudin-1 expression in colon
cancer cell lines induced changes in cellular phenotype, with
structural and functional changes in markers of epithelial-
mesenchymal transition (EMT) and had signiﬁcant eﬀects
upon the growth of xenografted tumors and metastasis in
athymic mice. Notably, regulation of E-cadherin expression
and β-catenin/Tcf signaling emerged as one of the poten-
tial mechanism underlying claudin-1– dependent changes
and thereby suggested complex interplay between diﬀerent
cell-cell adhesion molecules [59] .T h e r ei sa c c u m u l a t i n g
evidence that the regulation of gene expression of tight
junction proteins by the Wnt signaling pathway is part of a
mechanism essential for the diﬀerentiation of epithelial cells,
whichisimbalancedinoncogenictransformation.Moreover,
Wnt dependent signal transduction may be one way to
inﬂuence barrier function which is essentially determined
by the epithelial tight junctions. During recent years, a
number of components found in junctional complexes of
polarized epithelial cells have been shown to have signaling
functions involved in cell growth and diﬀerentiation [64].
Activation of the Wnt pathway leads to the stabilization
of β-catenin, which subsequently translocates into the cell
nucleus and regulates gene expression in association with
the lymphoid enhancer factor (LEF)/T-cell factor (TCF)
family of transcription factors [65]. LEF/TCF are nuclear
eﬀectorsoftheWingless(Wg)/Wntsignalingpathway,which
is involved in the regulation of cell fate, diﬀerentiation,
and polarization [66, 67]. Mutations in the gene for the
adenomatouspolyposiscoli(APC)tumorsuppressorprotein
stabilizes β-catenin and are supposed to be crucial events in
oncogenic transformation of intestinal epithelial cells, which
maydevelopintoadenomasandcarcinomas[68].Expression
of speciﬁc claudin family members can be regulated by Wnt
signaling pathway. Claudin-1 and claudin-2 are shown to
be target genes regulated by β-catenin signaling [69, 70].
Not only did expression of claudin-1 decreased signiﬁcantly
in response to the reduction of intracellular β-catenin by
adenovirus mediated transfer of wild-type APC into the
APC-deﬁcient colon cancer cells, but also two putative Tcf4
binding elements in the 5’ ﬂanking region of claudin-1 were
conﬁrmed to be responsible for activating its transcription
[69]. Further, nuclear eﬀectors of the Wnt signaling pathway
bind directly to the claudin-2 promoter region and thereby
enhance claudin-2 promoter activity. They further demon-
strated a crosstalk between the Wnt signaling pathway and
Cdxrelatedtranscriptionalactivationwithregardtoclaudin-
2 promoter-mediated gene expression [70]. This suggests
that Wnt signaling directly regulates the claudin-2 promoter
via the LEF-1/β-catenin complex and indirectly enhances
claudin-2 gene expression by transcription activation of
Cdx1. Importantly, gene expression of another component
of the tight junction complex, ZO-1, was suppressed after
transient expression of β-catenin into human colonic cancer
cell lines with low endogenous β-catenin, which is suggested
to contribute to a loss of epithelial polarization in neoplastic
cells[70].Further,mutationoftheAPC gene(thus,β-catenin
activation and nuclear translocation) is present in majority
of the human colorectal carcinomas [71]. It is further
interesting that colon cancer cells that expressed claudin-1
(HT29, SW480, and SW620) all harbor mutations in APC
and have activated β-catenin/Tcf signaling. By contrast, RIE
and HCT116 cells express wild-type APC [72], and neither
cell line expresses detectable levels of claudin-1, and thus
indicated thatAPC protein canregulate claudin-1 expression
in β-catenin/Tcf dependent/independent manner. Similar
dependence of claudin-1 expression in colon cancer cells
upon APC and β-catenin signaling was also shown by others
[69]. Metastasis is a complex phenomenon that requires
a number of speciﬁc steps such as decreased adhesion,
increased motility and invasion, proteolysis, and resistance
to apoptosis [73]. Claudins expression increase the migra-
tion/motilityasshownbybothBoydenchamberandwound-
healing assays [59, 74]. Claudin-5 promotes processing of
pro-MMP-2byMT1-MMP.Expressionofclaudin-5notonly
replaced TIMP-2 in pro-MMP-2 activation by MT1-MMP
but also promoted activation of pro-MMP-2 mediated by
all MT-MMPs and MT1-MMP mutants lacking the trans-
membrane domain (DeltaMT1-MMP) [75]. Stimulation of
MT-MMP-mediated proMMP-2 activation is also reported
with other claudin family members including claudin-1, -
2, and -3 [59, 75]. Amino acid substitutions or deletions
in the ectodomain of claudin-1 abolished this stimulatory
eﬀect and direct interaction of claudin-1 with MT1-MMP
and MMP-2 was demonstrated using immunoprecipitation.
MT1-MMP was colocalized with claudin-1 not only at
cell-cell borders, but also at other parts of the cell [75].
Thus it appears that interaction of MMP with claudins
might play an important role in tumorigenesis, invasion
and metastasis mediated by claudin expression. In our
studies, we observed that overexpression of claudin-1 in
colon cancer cells increased activity of both MMP-2 and
MMP-9whileinhibition ofclaudin-1resultedinasigniﬁcant6 Journal of Oncology
Table 1: Expression of Claudins in Cancer.
Type of Malignancy Claudin gene Expression
Breast Carcinoma
CLDN1 Down
CLDN3 Up
CLDN4 Up
CLDN7 Down
Biliary tract Carcinoma CLDN4 Up
Colorectal Carcinoma
CLDN1 Up
CLDN8 Down
CLDN12 Up
Endometrial endometrioid Carcinoma CLDN1 Down
CLDN2 Up
Endometrial seropapillary Carcinoma CLDN1 Up
CLDN2 Down
Gastric adenocarcinoma
CLDN1 Up
CLDN3 Up
CLDN4 Up
CLDN5 Up
Hepatocellular carcinoma CLDN4 Down
CLDN7 Up
Hepatoblastoma (Fetal)
CLDN1 Up
CLDN2 Up
CLDN3 Down
CLDN4 Down
CLDN7 Down
Head & Neck (SCC) CLDN7 Down
Lung cancer (Adenocarcinoma) CLDN1 Down
CLDN5 Up
Lung cancer (SCC) CLDN1 Up
CLDN5 Down
Meningioma CLDN1 Up
Mesothelioma CLDN4 Down
CLDN5 Down
Metastatic Melanoma CLDN1 Down
Oncocytoma CLDN7 Down
CLDN8 Up
Ovarian epithelial Carcinoma
CLDN1 Up
CLDN3 Up
CLDN4 Up
CLDN5 Up
CLDN7 Up
Ovarian sex cord stromal Tumors
CLDN1 Down
CLDN3 Down
CLDN4 Down
CLDN5 Down
Pancreatic Carcinoma CLDN1 Up
CLDN4 Up
Pleura (metastatic adenocarcinoma) CLDN3 UP
CLDN4 UP
Prostate Carcinoma
CLDN1 Up
CLDN2 Down
CLDN3 Up
CLDN4 UpJournal of Oncology 7
Table 1: Continued.
Type of Malignancy Claudin gene Expression
CLDN5 Down
CLDN7 Up
Renal cell Carcinoma
CLDN1 Up
CLDN3 Up
CLDN4 Up
Renal cell Carcinoma (Chromobhobe) CLDN7 Up
Tongue (SCC)
CLDN1 Up
CLDN4 Up
CLDN7 Up
Thyroid Carcinomas
CLDN1 Up
CLDN4 Up
CLDN7 Up
Undiﬀerentiated Thyroid Carcinoma CLDN1 Down
decrease in MMP-9 activity [59]. Similarly, overexpression
of claudin-3 or 4 in ovarian epithelial cells increased matrix
metalloproteinase-2 (MMP-2) activity [57].
Claudin expression and functions are regulated at multi-
ple levels and by diverse mechanisms [64, 76]. Delocalization
of claudins from membrane appears to be common among
the transformed cells [59, 77]. Constitutive activation of Ras
or Ras-mediated signaling pathway/s is one of the initial
steps during tumorigenesis that is causatively associated
with neoplastic transformation. In Ha-Ras overexpressing
MDCK cells, tight junction proteins claudin-1, occluding,
and ZO-1 were absent from the cell-cell contact sites but
were present in the cytoplasm [78]. Inhibition of MEK1
activity recruited all three proteins to the cell membrane
leading to a restoration of the tight junction barrier function
in MDCK cells [78]. However, in yet another study though
using breast cancer cells, MEK1 inhibition neither aﬀected
the mRNA or protein levels of claudin-1, occludin and/or
ZO-1 nor altered the subcellular cytoplasmic distribution
of claudin-1 to be more membrane speciﬁc [79]. Further,
studies have implicated protein kinase C in the regulation
of TJs through phorbol ester stimulation [80, 81]. Also,
PKA-dependentregulationofTJswasrecentlydemonstrated.
Claudin-3 and -4 can be phosphorylated in ovarian cancer
cells by PKA, a kinase frequently activated in ovarian cancer
[82]( Figure 3). Furthermore, modulation of MAP Kinase
signaling speciﬁcally ERK 1/2 and P-P38 as well as PI-3
Kinase have profound eﬀect upon tight junction sealing and
claudin expression [83]. Similarly, lysine deﬁcient protein
kinase 4 (WNK4) can phosphorylate multiple claudins and
increase paracellular permeability [84]. Most claudin pro-
teins have putative serine and/or threonine phosphorylation
sites in their cytoplasmic carboxy-terminal domains. The
consequences of the diﬀerential modulation brought about
by these kinases on these claudins remain to be determined
but may contribute to ovarian tumorigenesis.
Growth Factor receptors that are important in the regu-
lation of cell proliferation and survival including EGF, HGF
and IGF receptors regulate claudin expression and cellular
distribution though once again in cell/tissue speciﬁc manner
[85–88]. In addition, recent studies related to intestinal
inﬂammation have suggested roles of cytokines including
TNF-α,I N F - γ, IL-13 in the regulation of claudins expression
[89].
Endocytic recycling of claudin proteins is also a potential
mechanism of claudin regulation [90], and palmitoylation
[91] of these proteins has also been found to inﬂuence
claudin protein stability. At the transcriptional level, tran-
scription factors such as Snail [92], Cdx-2, HNF-α,a n d
GATA-4 [93, 94] can bind to the promoter regions of various
claudin genes and aﬀect their expression. Furthermore, we
have shown that colonic claudin-1 transcripts are regulated
by Smad-4, a known tumor suppressor as well as HDAC
inhibitors and thus support a complex regulation at multiple
levels [95, 96].
5. Conclusion
Irrespective of the diverse source of cancer growth and/or
heterogeneity among cancer patients regarding the cancer
originated from the same tissue source, it is well accepted
that Epithelial to Mesenchymal Transition (EMT) is a
cellular event central to the initiation and progression of
tumorigenesis. This raises the question: what these diverse
cancers have in common? Importantly, majority of cancer-
related deaths result from the cancers of epithelial origin
and include cancers of the colon, prostate, bladder, lung,
esophagus, breast, pancreas, ovary, and liver. Although their
diﬀerentiated properties vary, they are all composed prin-
cipally of epithelial cells which share similar basic features
including polarity and barrier function. So, the question
arises: what underlie the diﬀerential properties and/or
response to the cancer therapy between cancers originated
fromdiﬀerentepithelialorgansirrespectiveofthesimilarities
among their basic building units and their properties? Cell-
cell adhesion weakens or is lost during the process of EMT
or as dediﬀerentiation of epithelial cells. A critical role of
E-cadherin, principal constituent of adherens junction, in
the regulation of EMT is known, however it does not help
understand the diversity/heterogeneity among the cancers8 Journal of Oncology
of epithelial origin. Importantly, claudins are expressed in
the epithelial cells and in a tissue-speciﬁc manner and
changes among claudin family members in cancer follow
tissue-speciﬁc and sometimes contrasting pattern. Thus,
claudin family of proteins may hold the potential cue to
the heterogeneity among the tumors of epithelial origin
and beyond being useful markers may also help provide
therapeutic opportunities suited for speciﬁc cancer type.
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